Browsing Artículos (Medicina) by Subject "Biosimilar agent"
Now showing items 1-2 of 2
-
Article
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
(Aran Ediciones S.A., 2018)Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of ...
-
Article
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results
(Lippincott Williams & Wilkins, 2017)Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory ...